Clinical trial · Observational

Quantification of the Time and Effort Required for Peripheral Blood Stem Cell Collection -The European Perspective

Quantification of the Time and Effort Required for Peripheral Blood Stem Cell Collection - The European Perspective

NCT02287012CI-TRIAL-00024198completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

This study aims to observe the effects of the availability of plerixafor on the time and effort associated with autologous peripheral blood stem cell collection.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Lymphoma	Lymphoma	ONTOLOGY_EXACT	0.90

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
Time/Motion evaluation of actual apheresis	Other	—	UNRESOLVED

Design

Arms and outcomes

Arms (2)

label
Pre-Plerixafor era
description
The first era (Pre-Plerixafor era) will be defined as a two year period immediately preceding commercialization of plerixafor in Europe, (e.g., June 1, 2007 through June 1, 2009).
label
Plerixafor era
description
The second era (Plerixafor era) will be defined as July 1, 2010 through July 1, 2012).
interventionNames
1. Other: Time/Motion evaluation of actual apheresis

Primary outcomes (2)

measure
Type, duration and length of administration of mobilizing agents
timeFrame
one week
description
Number of visits for administration of mobilizing agents Duration (days) of administration of mobilizing agents Type of agents used as mobilizing agents
measure

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years

Show eligibility criteria text

Inclusion Criteria:

Patients must satisfy the following for the part 1

* Oncology patients diagnosed with Non-Hodgkin lymphoma who are candidates for autologous hematopoietic stem cell transplantation (HSCT)
* A patient that fails to achieve a target CD34+\>20 cells/µl, before or on the first day of apheresis
* Age \> 18 years

Exclusion Criteria for the part 1

Patients with:

* Age \< 18 years;
* Primary diagnosis other than Non-Hodgkin lymphoma
* Undergone prior autologous hematopoietic stem cell transplantation (HSCT)

References

Publications (0)

Data not yet available

No reference posted for this study.